With the increasing interest in polymeric nano particles for biomedical applications, there is a need for continuous flow methodologies that allow for the precise control of nanoparticle synthesis. Poly(lactide coglycolic) acid (PLGA) nanoparticles with diameters of 220-250 nm were synthesized using a labonachip, exploiting the precise flow control offered by a millifluidic platform. The association and the effect of PLGA nanopar ticles on red blood cells (RBCs) were compared for fluores cent PLGA nanoparticles made by this novel continuous flow process using a millifluidic chip and smaller PLGA nanoparticles made by a batch method. Results indicated that all PLGA nanoparticles studied, independent of the synthesis method and size, adhered to the surface of RBCs but had no significant hemolytic effect at concentrations lower than 10 mg/ml.
Introduction
Nanoparticles play an increasingly important role in drug delivery [1] . Polymeric nanoparticles in particular have garnered extraordinary interest as drug delivery systems because of their controllable physicalchemical character istics and their ability to entrap, dissolve, or target drugs [2] . Hydrophilic drugs, hydrophobic drugs, proteins, vaccines, and biological macromolecules can be delivered with bio compatible and biodegradable polymeric nanoparticles [3] .
Poly(lacticcoglycolic acid) (PLGA) is a frequently used polymeric compound composed of glycolic acid and lactic acid, approved by the US Food and Drug Admin istration (FDA) for drug delivery and therapeutic encap sulation [4] . PLGA is known for its biocompatibility and biodegradability [5] , as it breaks down into monomer acids metabolized through natural pathways. The size and the size distribution of the PLGA nanoparticles can be determined using various synthesis methods [6] . Batch methods such as emulsion evaporation, emulsion diffu sion, and nanoprecipitation are common techniques used to synthesize nanoparticles from the preformed PLGA polymer.
Emulsion evaporation is one of the most commonly used methods to synthesize polymeric nanoparticles. In this method, the emulsification of a nonpolar organic phase in an aqueous phase containing the surfactant is followed by the evaporation of the organic solvent. Usually, the polymer and active components are dissolved in a suitable solvent to form the organic phase (e.g. ethyl acetate and dichloromethane), which is mixed with water under high pressure (e.g. microfluidization) or sonica tion to form an emulsion. Finally, the organic solvent is removed by evaporation under vacuum.
Nanoprecipitation is another common batch tech nique often used to synthesize nanoparticles. Typically, the polymer is dissolved in a polar, watermiscible solvent such as acetone, acetonitrile, ethanol, or methanol. The organic solution is then poured into an aqueous solu tion containing surfactants. In this process, polymeric nanoparticles are quickly formed through rapid solvent diffusion to the aqueous phase with further polymer precipitation. The method requires the extraction of the organic solvent by evaporation as well, but it uses sol vents that are less toxic [6] .
The nanoprecipitation technique has been converged with different continuous flow labonachip devices for particle synthesis. Microfluidic platforms offer reaction environments that are precisely controlled at the micro scale level and can be reproduced easily and also allow systematic tuning of the biophysical properties of nano particles [7] . Because of the increased speed of analysis, parallel screening, welldefined and repeatable condi tions, and lower cost of research, microfluidic platforms are attractive in the preparation of nanoparticles and in the study of their interaction with biological systems [8] . Karnik et al. [9] demonstrated the use of the continuous flow method in nanoparticle synthesis using microflu idic channels to synthesize PLGAPEG nanoparticles with diameters in the range of 10-50 nm. A fluidic nanoprecipi tation system constructed with an inlet channel feeding the center of a dispersing channel (3/32″) was used to fab ricate uniform PLGA particles in the range of 140-500 nm [10] . As stated in the work performed by Wang et al. [11] , the sizecontrolled synthesis of PLGA nanoparticles ranging from 55 to 135 nm diameter has been accom plished using the tubing method. It was reported that nanoparticles produced at a high flow rate were smaller than those produced at a lower flow rate [11] . A parallel 3D hydrodynamic flow focusing device using a multilayer microfluidic system was used to synthesize PLGAPEG nanoparticles within the range of sizes (13-150 nm) [7] .
Alternatively, millifluidic chips provide a scaledup version of microfluidics and offer additional advantages over microfluidics as they are less expensive, have more area for chemical reactions, and are capable of provid ing more precise control over fluid flow. Several research groups have used a labonachip platform for synthesis of inorganic nanoparticles in a continuous flow configu ration [12] [13] [14] [15] , but few have focused on polymeric nano particles. In the literature, millifluidic reactors have been used to synthesize larger (100 μm to 3 mm) polymeric par ticles with narrow size distributions and a large variety of shapes, dimensions, and compositions [16] . This research has successfully demonstrated the use of continuous flow technique in a millifluidic platform to synthesize nanoparticles with similar surface properties of that of batch synthesized nanoparticles. The present paper has assessed the hemolytic effect of these nanoparticles on red blood cells (RBCs).
When PLGA nanoparticles are administered to humans through oral, nasal, intramuscular, or intrave nous routes, some particles will make their way into the blood. How these nanoparticles associate with and affect RBCs is a health concern because RBCs are among the first cells to interact with foreign materials present in the circulatory system [17] . Only a few studies have been pub lished on the compatibility of PLGA nanoparticles with RBCs in general, and all have studied the interaction and effect on RBCs of PLGA nanoparticles made with batch methods [5, [17] [18] [19] .
Overall, the literature published indicates that PLGA nanoparticles at certain concentrations affect erythro cyte hemolysis. Most studies were conducted at low NP concentration (μg/ml levels) and found no toxicity of PLGA nanoparticles on RBCs. The effects of the synthesis process (continuous flow compared with batch process ing) on the particle association and compatibility with RBCs have not been reported. The main objective of this study was to assess the concentration and sizedependent interaction of PLGA particles prepared in continuous flow mode via a millifluidic platform versus PLGA particles synthesized by a batch process with RBC. The emulsion evaporation method was used for batch processing, as the emulsification process resulted in smaller sized nanopar ticles compared with the continuous flow nanoprecipita tion technique. The main hypothesis of this experiment was that the hemolytic effect of PLGA nanoparticles made by two synthesis methodologies, a batch emulsion evapo ration method and a continuous flow method using a mil lifluidic labonachip device, is influenced by size and size distribution.
Materials and methods

Materials
Poly(d,llactidecoglycolic) acid (PLGA) polymer, poly vinyl alcohol (PVA), fluorescein isothiocyanate (FITC), 1[bis(dimethylamino)methylene]1H1,2,3triazolo [4,5b] pyridinium3oxid hexafluorophosphate (HATU), N,N diisopropylethylamine (DIPEA), NBocethylenediamine, and trifluoroacetic acid (TFA) were purchased from Sigma Aldrich (Sigma Chemical Co. Ltd., St. Louis, MO). Dichlo romethane (DCM), acetone, and ethanol were HPLC grade and supplied by Mallinckrodt Baker (Pittsburg, NJ). Phos phatebuffered saline (PBS) was purchased from Ther moFisher Scientific (Waltham, MA). Nanopure water was obtained using Nanopure Diamond System (Barnstead International, Dubuque, IA). All other reagents and com ponents used in this study were analytical grade.
A Nemesys syringe pump used to control the flow rate of the organic and aqueous phase during synthesis was purchased from Cetoni GmbH (Gewerbegebiet Korb wiesen, Korbussen, Germany), and the millifluidic chip was fabricated in the J. Bennett Johnston Sr. Center for Advanced Microstructures and Devices (CAMD, LSU).
The millifluidic chip used in the study was prepared using a polyvinyldene fluoride (PVDF) polymer. This is a siliconbased organic polymer and is, in general, inert, nontoxic, and nonflammable. The millifluidic chip con sisted of a serpentine channel with dimensions of 2 mm (W) × 0.15 mm (H) × 220 mm (L) [14] . This chip has two inlets and a single outlet, which can be connected to the syringe pump using the manifold. The flow rates of the solution were computer controlled.
Methods
Synthesis of PLGA-FITC polymer
PLGA was conjugated with FITC to visualize the attach ment of the nanoparticles to RBCs using microscopy and to facilitate the nanoparticles tracking by flow cytometry (FC). FITC was conjugated to the terminal group of PLGA as follows. First, 1 g of PLGA was dissolved in 20 ml DCM at room temperature, which was followed by the addi tion of 55 mg of HATU, 24 mg of NBocethylenediamine, and 0.2 ml of DIPEA. The suspension was stirred for 12 h at room temperature. One hundred milliliters of distilled water was added to stop the reaction, and the solution was poured into 200 ml ethanol, which resulted in the precipitation of PLGANHBoc. Next, the precipitate was dissolved in 15 ml DCM followed by addition of TFA, in 1:1 vol/vol ratio of DCM to TFA. After 25 min at room tempera ture, the solution was poured into 200 ml ethanol and left to dry overnight. The final step was a conjugation of PLGA NH 2 to FITC. Twenty milliliters of DCM containing 0.075 ml DIPEA was used to dissolve PLGANH 2 polymer. When the polymer dissolved, 30 mg of FITC was added and left to react for 8 h. The organic phase was washed with water in a separation funnel and poured into 100 ml of ethanol. Excess untreated FITC was removed by washing the pre cipitate for six times. The solid precipitates were dried for 30 h under high vacuum and placed at -20°C for further use in polymeric nanoparticles synthesis [20] .
Synthesis of PLGA nanoparticles
Batch processing (emulsion evaporation method)
Emulsion evaporation method was used to synthesize PLGA nanoparticles as follows. The PLGA polymer was dissolved in ethyl acetate at 20 mg/ml and vortexed for 30-45 min to form the organic phase. The organic phase was poured into the aqueous phase consisting of 2% PVA and stirred. Emulsification was conducted under high shear stress in a microfluidizer highshear fluid proces sor (Microfluidics Newton, MA, USA). Next, evaporation was performed in a rotovapor (Buchi R124; Buchi Analyti cal Inc., New Castle, DE, USA) for 45 min under vacuum to remove ethyl acetate. To remove the excess PVA, the resulting PLGA nanoparticle suspension was placed in a dialysis membrane and suspended in nanopure water for 48 h with several water changes at room temperature. Trehalose was added in the ratio of 1:1 with the weight of PLGA and PVA used to the suspension. The suspension was frozen at -80°C for 2 h in an incubator, and the sample was then freeze dried in 2.5Plus FreeZone (Labconco Inc., Kansas City, MO, USA) and stored at -20°C until further analysis.
Batch processing (nanoprecipitation method)
PLGA nanoparticles were also prepared by the conven tional bulk nanoprecipitation method [11] , and their char acteristics were compared against PLGA nanoparticles synthesized using the millifluidic chip. The organic phase (500, 250, 167, and 125 μl) with a PLGA concentration of 20 mg/ml in acetonitrile was added dropwise into four vials containing 5 ml of the aqueous phase to maintain the aqueous phase to organic phase ratio (10:1, 20:1, 30:1, and 40:1 v/v); the emulsion was stirred for 3 min at room temperature and left to evaporate at room temperature.
Continuous flow processing (millifluidic synthesis)
PLGA nanoparticles were synthesized by continuous flow in a millifluidic chip as follows. The organic phase was formed by dissolving PLGA in acetonitrile at 20 mg/ml and mixing for 30-45 min. The water phase consisted of a 2% PVA solution. The organic phase and the aqueous phase were pumped through the channel of the milliflu idic chip using the Nemesys pump. PLGA nanoparticles were synthesized at different flow rates of aqueous phase and varying aqueous-organic phase ratio (10:1, 20:1, 30:1, and 40:1 v/v), with PVA as the surfactant. The sample was collected at the outlet in a vial. Next, evaporation was performed in a rotovapor (Buchi R124, Buchi Analytical Inc.) for 45 min under vacuum to remove acetone. The resulting PLGA nanoparticle suspension was placed in the dialysis membrane for 48 h with the dialysis medium changed every 8 h to remove excess surfactants. Trehalose was added to the suspension after dialysis in the ratio of 1:1 with the weight of PLGA and PVA used. The suspension was frozen at -80°C for 2 h in an incubator, and the sample was then freeze dried in 2.5Plus FreeZone (Labconco Inc., Kansas City, MO, USA) and stored at -20°C until further analysis.
Particle size, size distribution, and zeta potential analysis
Freshly prepared PLGA nanoparticles were character ized by dynamic light scattering (DLS) using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Worces tershire, UK) to measure the average particle size, poly dispersity index (PDI), and zeta potential. Before the measurements were taken, samples were diluted to a final concentration of 0.2 mg/ml. All measurements were per formed in triplicate.
Blood handling
Fresh blood samples used for the experiment were acquired from 7weekold SpragueDawley rats. The Loui siana State University, School of Medicine, provided the fresh blood samples in a sodium heparin blood collection tube. A volume of 2-3 ml of blood was obtained at a time, and the blood samples were used within 48 h of availabil ity. Blood samples not used on the first day were stored in the refrigerator. For FC, RBCs were separated from other components in the fresh blood samples. A volume of 0.5 ml of blood sample was centrifuged at 1000 rpm for 10 min, and the supernatant was removed. The remaining RBCs were washed with 2 ml of PBS, centrifuged at 1000 rpm for 5 min, and resuspended in PBS 3 times.
For the hemolytic assay, whole blood was diluted in PBS such that the hemoglobin concentration was 10 mg/ml.
Nanoparticle-blood cell association FC
FC was used to quantify the PLGA nanoparticles asso ciation with RBCs. Before FC analysis, 0.5 ml of blood was washed with 1 ml of PBS. The washed blood sample was centrifuged at 1000 rpm for 5 min [21] . One hundred microliters of the precipitated RBCs was suspended in 700 μl of PBS. PLGAFITC nanoparticle suspensions were prepared at various concentrations, 2, 3, 5, and 10 mg/ml. A volume of 100 μl of PLGAFITC nanoparticle suspension was added, and the mixture was placed in a water bath set to 37°C for 3 h. Next, 100 μl of sample was removed and mixed with 1 ml PBS to dilute the RBCs. Samples were analyzed using a Becton Dickinson FACS Aria (Becton Dickinson, San Francisco, CA). Approximately 100,000 RBCs were examined by the software. FACScan and Cell Quest analyzing software (Becton Dickinson) was used to prepare scatter plots of side scatter (SSC) versus forward scatter (FSC) and side scatter versus fluorescence inten sity of FITC. An FSC histogram was generated.
Hemolytic characterization
The hemolytic characteristics of PLGAPVA nanoparti cles were evaluated by the ASTM E252408 Standard Test Method for Analysis of Hemolytic Properties of nanopar ticles [22] . A Hemoglobin Reagent Set from Teco Diag nostics (Teco Diagnostics, Anaheim, CA) was used. First, standard curve was generated by preparing hemoglobin standards concentrations covering a range of concentra tions of 1-150 mg/ml. Blood was diluted in PBS to a hemo globin concentration of approximately 10 mg/ml. In a test tube, 700 μl of PBS, 100 μl of diluted blood, and 100 μl of PLGAPVA nanoparticle were mixed and placed on an orbital shaker for 30 min and stored in a water bath set to 37°C for 3 h. After that, the samples were centrifuged for 15 min at 800 g. Then 100 μl of supernatant was added to a 96well plate with 100 μl of cyanmethemoglobin reagent. The mixture was allowed to react for 10 min with gentle shakes; then the absorbance of sample was measured on a Perkin Elmer Wallac Victor2 plate reader (Waltham, MA) at 540 nm. This absorbance compared with the standard curve was used to determine hemoglobin concentration. To quantify percent hemolysis, the hemoglobin concen tration measured was divided by the hemoglobin concen tration of the diluted blood solution as described by the following equation: = × Hemoglobin conc. of sample % Hemolysis 1 00. Hemoglobin conc. of diluted blood For positive control, cells exposed to a 10% Triton X solution were used. All measurements were performed in triplicate, and known standards were run with each sample to ensure they correlated properly with the stand ard curve.
Statistics
Statistical analysis was conducted using JMP Pro 12 software (SAS Institute Inc., Cary, NC). Comparison between different groups of data was conducted using TukeyKramer HSD test, and the statistical differ ences between groups were judged to be significant at pvalue < 0.05 after analysis of variance. All the results are expressed as mean ± SD.
Results
Nanoparticle characterization
DLS characterization
PLGA nanoparticles were synthesized by the conven tional bulk nanoprecipitation method and by using the millifluidics chip at different flow rates of aqueous phase and varying aqueousorganic phase ratio and different flow rate ratio (10:1, 20:1, 30:1, and 40:1 v/v), respectively, with PVA as the surfactant. The size, the polydispersity, and the zeta potential of nanoparticles prepared by each method were measured and compared with optimize the nanoparticle synthesis on the millifluidic chip (Figure 1) .
The minimum average size of nanoparticles synthe sized using the continuous flow method at different flow rates was larger than the nanoparticles prepared with batch nanoprecipitation method, but in the same range and higher flow rate ratio (40:1 v/v) were close in size to nanoparticles synthesized using the batch processing method at that aqueousorganic phase ratio (Figure 1) . Increasing the flow rate of the aqueous phase and flow rate ratio allowed for ~ 200 nm nanoparticles to be pre pared. PLGA nanoparticles synthesized by continuous flow method had a zeta potential of -11.67 ± 0.02 mV. PLGA nano particles synthesized with batch nanoprecipitation method had similar zeta potential of -9.71 ± 0.75 mV. In addition to the PLGA nanoparticles of approxi mately 200 nm with PDI of 0.199 ± 0.028 synthesized by continuous flow on the millifluidic chip, smaller PLGA nanoparticles were made by batch processing via emul sion evaporation method using ethyl acetate as organic phase (120 nm, PDI 0.17 ± 0.02) and were negatively charged (-20 ± 1.10 mV) ( Table 1) .
Nanoparticle-RBC interaction
Nanoparticles-RBC association -FC analysis
Nanoparticles synthesized using batch processing with emulsion evaporation (~ 120 nm) and continuous flow in millifluidics chip (~ 200 nm) were used to study the nano particlesRBC association. FC analysis showed that the interaction of RBCs with PLGA for nanoparticles synthe sized by continuous flow was concentration dependent, as indicated by the SSC and intensity of FITC change upon exposure of RBCs to PLGA nanoparticles (Figure 2) .
When RBCs were treated with higher concentration of nanoparticles, more nanoparticles attached to the surface of the RBCs (Figure 3 ). The intensity of light emitted by RBCs shifted to the area with FITCspecific signal; the shift was more pronounced with increasing concentra tion of nanoparticles. The FITC intensity histogram for blood samples exposed to batch processed nanoparticle Representative FITC intensity histograms of the blood samples exposed to fluorescent PLGA nanoparticles at different concentrations for 200 nm nanoparticles, as follows: untreated blood (A) and blood exposed to nanoparticles at 2 mg/ml (B), 3 mg/ml (C), 5 mg/ml (D), and 10 mg/ml (E). M1 represents the population with specific signal over control. (emulsion evaporation synthesized) PLGA nanoparticles was similar (data not shown) to that for nanoparticles syn thesized in continuous flow. In both cases, FITC intensity histograms suggested that at higher nanoparticle concen tration, more nanoparticles associated with the RBCs. Of 100,000 cells counted in each experiment, only 0.22% gave a fluorescence signal for control (blood without nanoparticles). By contrast, when exposed to nanoparticles synthesized by the continuous flow method at concentrations of 2, 3, 5, and 10 mg/ml, the fraction of RBCs with a fluorescence signal in the FITCspecific section was 13.95%, 17.41%, 23.32%, and 37.21%, respec tively. Similarly, the blood cells treated with batch pro cessing synthesized nanoparticles gave a fluorescence signal of 15.23%, 18.27%, 29.92%, and 34.32% for nano particle concentrations of 2, 3, 5, and 10 mg/ml. In both cases, the fluorescence signal increased with increasing nanoparticle concentrations.
Statistical analysis showed that the results were sig nificantly different for all nanoparticle concentrations relative to the control (pvalue < 0.05). When nanoparti cleRBC association was compared for continuous flow and batch processing synthesized nanoparticles at the same concentration, it was observed that for nanoparticle concentration of 2 and 3 mg/ml, there was no significant difference (pvalue > 0.05) between treatments, whereas at concentrations higher than 3 mg/ml, the difference was significant. Bigger PLGA nanoparticles made by the continuous flow synthesis had, in general, a lower associ ation with RBCs than the smaller batchmade PLGA nano particles (Figure 3 ).
Hemolytic assay
PLGA nanoparticles in contact with diluted human blood for 3 h 15 min induced hemolysis, detected as increased absorbance intensity with increasing concentration of nanoparticles in the PBS/blood mixture (Figure 4 ). Nano particle samples at the highest concentrations (10 mg/ml) caused no significant level of hemolysis than the negative control for both continuous flow and batch processing synthesized nanoparticles.
Nontreated blood samples (negative control) showed nearly 16% and 20% hemolysis because of simple han dling and sample preparation when the experiment was conducted for continuous flow synthesized nanoparti cles and for batch processed nanoparticles, respectively. Taking the negative control as a baseline, nanoparticles Figure 4 : In vitro hemolysis of rat blood exposed to different concentrations of PLGA nanoparticles. Untreated blood sample was used as the negative control (-), and Triton X-10% treated blood was used as the positive control (+). Data are presented as means ± SD, n = 3. made by continuous flow caused 17%-18% hemolysis of RBCs, whereas batch processed nanoparticles caused 20%-22% hemolysis. In hemolysis at the highest nanopar ticle concentrations tested, 10 mg/ml was not significantly different from the negative control in both cases (Figure 4) . Nanoparticle concentration lower than 10 mg/ml did not induce any significant hemolysis in the diluted blood exposed to the nanoparticles. Blood samples were collected on different days for the two different experiments and from different rats of the same species. This may have contributed to the differ ence observed between the baseline and the results at the same nanoparticle concentration for continuous flow and batch processing synthesized nanoparticles. Therefore, the% change hemolysis was compared for the two types of particles studied. On the basis of the% change hemolysis as a function of nanoparticle concentration, it was noted that for all the concentrations, the hemolytic profile was not significantly different for continuous flow and batch processing synthesized nanoparticles except for 3 mg/ml. The hemotoxic effect increased by only 10.85% ± 1.34% and 13.01% ± 1.42% at 10 mg/ml nanoparticle concentra tion, with batch processed samples being associated with a slightly higher hemolysis ( Figure 5 ), most likely because of their smaller size.
According to the hemolysis criterion in ASTM E2524 08 standard, an increase in the percent hemolysis by more than 5% indicates damage to RBCs caused by the test materials [23] . Considering the baseline for the hemoly sis due to sample handling and preparation, the criteria in ASTM E252408 standard were not exceeded at smaller PLGA nanoparticle concentration (2, 3, and 5 mg/ml) for both synthesis methods. PLGA nanoparticles at higher concentrations of 10 mg/ml exceeded the criteria.
Discussions
The convergence and integration of continuous flow systems with particle technologies has shown consider able progress lately for the development of microparticles and nanoparticles [9] . Using a continuous flow method, nanoparticles in the range of 200 nm were synthesized, which is a significant improvement over other published millifluidic methodologies, reporting synthesis of larger polymeric particles in the range of 100 μm to 3 mm [16] . Nanoparticles formed at the higher flow rates using con tinuous flow in the present study were smaller than nano particles synthesized at lower flow rates. Similar results were reported by Wang et al. [11] , in which nanoparticles produced at a high flow rate were smaller than those pro duced at a lower flow rate.
Nanoparticles synthesized by the batch emulsion evaporation processing method were ~ 80 nm smaller than the nanoparticles synthesized by the continuous flow nan oprecipitation method. Highshear stress applied during the emulsification process in batch processing reduced the size of particles formed in the emulsion evaporation method, whereas the particles synthesized by continuous flow were formed instantaneously by rapid solvent diffu sion. Nanoparticles associated with RBCs in a concentra tiondependent manner in both cases. RBCs treated with a higher concentration of nanoparticles (10 mg/ml) showed 30% or more RBCs tagged with nanoparticles.
On the basis of different studies published, it has been established that although Au and platinum nanoparticles interacted with blood components without much effect, Ag nanoparticles caused cell damage [24, 25] , Cu nano particles tended to destroy the cell membrane and caused hemolysis of RBCs [26, 27] , Fe nanoparticles only influ enced the physiology of RBCs [28] , Sibased nanopar ticles also had adverse effects on the RBCs [29] [30] [31] [32] , and TiO 2 nanoparticles [33, 34] and MWCNTs had negative effect on the RBCs as well. Although the effect of inor ganic nanoparticles such as those described previously on RBCs was extensively covered in the literature, only a limited number of studies were published on the interac tion of polymeric nanoparticles with blood constituents (Table 2) .
Polymeric nanoparticles such as polystyrene nano particles, polymethacrylate nanoparticles, PEGylated and nonPEGylated copolymer conjugated nanoparticles, and nanoparticles of complex polymeric structures, such as those made of poly(3hydroxybutyrate)poly(ethylene glycol)poly(3hydroxyl butyrate) (PHBPEGPHB) and chitosanNtrimethylaminoethylmethacrylate chloride PEG copolymers, have been previously reported to have no hemotoxic and cytotoxic effect on RBCs [36] . Polym ethacrylate nanoparticles were found to have minimal cytotoxicity [37] . Similarly, complex polymeric structure PHBPEGPHB recorded no signs of cytotoxicity and hemotoxicity [38] (Table 3) . Lower nanoparticle concentrations up to 5 mg/ml did not induce significant hemolysis with either continuous flow or batch processing synthesized PLGA nanoparticles, as reported herein. The hemolytic assay suggested that when the concentration of the nanoparticles was higher than 5 mg/ml, nanoparticles induced hemotoxic effect on the RBCs for both cases. Similar to these results, pub lished literature on the interaction of erythrocytes with nanoparticles made from PLGA conjugated with alendro nate (PLGAALE nanoparticles) showed that PLGAALE nanoparticles were not cytotoxic and were suitable for intravenous administration at the lower concentrations of 560, 56, and 5.6 μg/ml [5] . Biomimetic mucin modified PLGA nanoparticles, studied for the hemocompatibility and cytocompatibility, showed that the RBCs exhibited favorable compatibility to both PLGA and modified nan oparticles; results indicated that interactions of PLGA nanoparticles with erythrocytes did not induce hemolysis under tested conditions [19] (Table 3) .
According to the hemolysis criterion in ASTM E2524 08 standard, an increase in the percent hemolysis by more than 5% indicates damage to RBCs caused by the test materials [23] . Considering the baseline for the hemoly sis due to sample handling and preparation, the criteria in ASTM E252408 standard were not exceeded at smaller PLGA nanoparticle concentration (2, 3, 5 mg/ml) for both synthesis methods.
Although RBC damage was encountered at nanopar ticle concentrations greater than 10 mg/ml, according to ASTM E252408 standard, it is important to note that this concentration is equivalent to a human dose of 50 g nanoparticle for an average man of 70 kg. This number was calculated taking into account that a typical male rat that weighs 300 g has a blood volume of 50 ml/kg [39] . Such high concentrations are too high to be relevant for biomedical applications, but the data presented are important in understanding the dose effect of PLGA nano particles on RBCs.
Conclusions
A continuous flow method, based on rapid solvent diffu sion for particle synthesis, has been explored in this work for the synthesis of nanoparticles in a millifluidic device. Flow rate and flow rate ratios played a critical role in con trolling the size of nanoparticles prepared in a continu ous flow synthesis. Nanoparticles with an average size of 200 nm and narrow size distribution were synthesized with the continuous method. Particles of 120 nm in diame ter were made by a batch method to provide a comparison. The continuous flow method provided the advantages of flow rate control, ratio of aqueous phase to organic phase, and mixing of the solutions for the synthesis of particles of different sizes compared with batch processing. The ability to control the nanoparticle properties by simply varying the synthesis parameters in a continuous flow method, in particular flow rate and aqueous-organic phase ratio, can open a new pathway for formulation of nanoparticles.
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